We are just one quarter into 2022 and the Food and Drug Administration (FDA) already has experienced a number of significant changes and developments. A new commissioner has been confirmed (Robert Califf, M.D., who previously served under President Obama). The user fee reauthorization process has kicked off on Capitol Hill. The pandemic continues to impact our country. And the Biden administration has released a budget with significant implications for the FDA. Those are just some of the critical issues involving the FDA—all of which touch every life sciences and health care organization in many ways.
In a new webinar, Manatt Health speaks with key FDA leaders—including Chief of Staff Julie Tierney and Associate Commissioner for Legislative Affairs Kim Trzeciak—about these and other topics. Critical questions the session will address include:
- What are Commissioner Califf’s priorities during his first year as commissioner under President Biden?
- What lessons has the FDA learned as a result of playing such a critical role throughout the pandemic?
- What are the FDA’s priorities within the user fee reauthorization process in Congress?
- What changes should the industry be preparing for in 2022—and beyond?
Even if you can’t make our original airing on April 29, register free now and you’ll receive a link to view the program on demand.
Rachel Sher, Partner, Manatt Health
Julie Tierney, Chief of Staff, FDA
Kim Trzeciak, Associate Commissioner for Legislative Affairs, FDA
Date and Time:
Friday, April 29
12:00 – 1:00 p.m. ET
If you would like to receive an audio transcript of this webinar due to accessibility issues, please email us at firstname.lastname@example.org.
This program does not constitute legal advice, nor does it establish an attorney-client relationship. Views expressed by presenters are strictly their own and should not be construed to be the views of Manatt or attributed to Manatt.